Hybrid Organ GmbH
Founded in 1996, Hybrid Organ initially focused on the development of
bioreactors for clinical systems and innovative biotechnological applications.
The underlying technology represents a platform for a wide range of biotechnological
purposes and allows vertical differentiation.
Currently, Hybrid Organ produces prototypes and a series of small scale
hollow fiber bioreactor systems, along with the necessary pump and control
devices. Our range of bioreactors contain either a 500 ml cell compartment
for clinical use, or a 50 ml, 8 ml or 1 ml cell compartment for analytical
In terms possible application, our products (and those still in the pipeline)
can be divided in three distinct product families:
* Bioreactor systems for medical therapies with cells.
* Bench top bioreactor systems for the production of therapeutic and diagnostic
substances using primary cells.
* Bioreactor systems for laboratory research and analytical purposes with
primary cells (cell-biology, pharmaceutical industry).
One of the company’s key areas of activity targeting medical therapies
is a hybrid liver support system with primary human cells to treat patients
with acute liver failure.
The market for therapeutic/diagnostic proteins has been saturated in a
number of areas. However, there is still a need for a system with the
ability to produce large quantities of proteins at a high quality, in
terms of post-translational protein modifications (e.g. glycosylation),
and which can compete economically with currently used systems. The product
Hybrid Organ is working on fills these specifications and will be able
to compete against existing systems.
In addition to these devices, which are based on hollow fiber technology,
alternative developments are currently at an early R&D stage:
* In collaboration with the Burn Center Berlin, Hybrid Organ is working
on the development of a flat sheet membrane bioreactor for skin cell culture.
This R&D project focuses skin replacement for burn patients based
on an autologous multi-layer skin product.
* Within a further collaboration with the Humboldt University of Berlin,
Charité, Hybrid Organ is developing a sponge structure bioreactor
based on a ceramic matrix for the expansion of blood stem cells (hybrid
bone marrow) and the production of blood cells.
* Another project funded by the German Federal Ministry for Education
and Research (BMBF) aims to develop and characterize immortalized human
liver cells in liver support therapy. The Hybrid Organ GmbH is a spin-off
of the Biomedical Research Center of the Humboldt University, Berlin and
maintains a close collaboration with the university in the form of job
sharing programs. The Transplantation Center at the Charité acts
as a partner for clinical studies.
The founders of Hybrid Organ GmbH are:
Thomas Bold, CEO
Prof. Peter Neuhaus, Director of the Berlin Transplantation Center
Prof. Jörg C. Gerlach, Director of Research at the Division of Experimental
Surgery at the Charité , Berlin
Both Prof. Neuhaus and Prof. Gerlach have extensive experience and expertise
in the fields of R&D.
Central Airport Berlin-Tempelhof
Tel.: ++49-30-6951 3500
Fax: ++49-30-6951 3509
02/ 1997 as GmbH (Handelsregister Berlin Charlottenburg: HR B 61621)
Seed capital DM 100.000,-
Equity capital DM 2,0 Mio (Innovationsfond Land Berlin, EFRE, TBG)
Funding: DM 1,9 Mio (GA, BMBF, Land Berlin)
Charité, Medical Faculty of the Humboldt University Berlin
Thomas Bold, CEO (Director)
Jörg C. Gerlach, MD, PhD (Director)
Peter Neuhaus, MD (Director)